Literature DB >> 1399000

Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

P M Melissen1, W van Vianen, I A Bakker-Woudenberg.   

Abstract

Administration of free muramyl tripeptide phosphatidylethanolamide (MTPPE) or liposome-encapsulated MTPPE (LE-MTPPE) in a twofold-lower dose at 24 h before bacterial inoculation resulted in clearance of intravenously inoculated Klebsiella pneumoniae by tissue macrophages, whereas in control mice, bacteria were not effectively cleared from the blood. In addition, MTPPE and LE-MTPPE led to increased numbers of leukocytes in the blood, which could compensate for the leukopenia in mice resulting from infection with K. pneumoniae. In an attempt to elucidate the relative contributions of the activation of tissue macrophages and the recruitment of leukocytes to the antibacterial resistance induced by MTPPE and LE-MTPPE, mice were infected intraperitoneally with K. pneumoniae. In these MTPPE- and LE-MTPPE treated mice, intraperitoneal influx of leukocytes and the phagocytic capacity of leukocytes were not higher than in untreated control mice. However, MTPPE- and LE-MTPPE-treated mice survived much longer; eventually 33% of the LE-MTPPE-treated mice survived, whereas all untreated control mice died as a result of bacterial septicemia. This prevention of early death appeared to be the result of an increased clearance of bacteria from the blood by activated tissue macrophages. It was observed that depletion of these tissue macrophages in liver and spleen abrogates the effect of LE-MTPPE treatment, indicating that tissue macrophages are of major importance in the LE-MTPPE-induced resistance against K. pneumoniae infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399000      PMCID: PMC258245          DOI: 10.1128/iai.60.11.4891-4897.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection.

Authors:  P M Melissen; W van Vianen; Y Rijsbergen; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

2.  Non-specific stimulation of host defenses against a bacterial challenge in malnourished hosts.

Authors:  R B Galland; H C Polk
Journal:  Br J Surg       Date:  1982-11       Impact factor: 6.939

3.  Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate.

Authors:  N Van Rooijen; N Kors; M vd Ende; C D Dijkstra
Journal:  Cell Tissue Res       Date:  1990-05       Impact factor: 5.249

4.  In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide.

Authors:  T Daemen; A Veninga; F H Roerdink; G L Scherphof
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

5.  Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model.

Authors:  J R Izbicki; C Raedler; A Anke; P Brunner; M Siebeck; E Leinisch; R Lüttiken; G Ruckdeschel; D K Wilker; L Schweiberer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

6.  Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.

Authors:  M A Parant; F M Audibert; L A Chedid; M R Level; P L Lefrancier; J P Choay; E Lederer
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

7.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

8.  Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination.

Authors:  N van Rooijen; N Kors; G Kraal
Journal:  J Leukoc Biol       Date:  1989-02       Impact factor: 4.962

9.  Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs.

Authors:  F M Dietrich; H K Hochkeppel; B Lukas
Journal:  Int J Immunopharmacol       Date:  1986

10.  Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.

Authors:  D Reisser; J F Jeannin; P Lagadec; F Martin
Journal:  J Biol Response Mod       Date:  1985-10
View more
  4 in total

1.  Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon.

Authors:  T L ten Hagen; W van Vianen; H F Savelkoul; H Heremans; W A Buurman; I A Bakker-Woudenberg
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 2.  Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.

Authors:  I A Bakker-Woudenberg; A F Lokerse; M T ten Kate; P M Melissen; W van Vianen; E W van Etten
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

Review 3.  Innate Host Defense against Klebsiella pneumoniae and the Outlook for Development of Immunotherapies.

Authors:  Clement Opoku-Temeng; Natalia Malachowa; Scott D Kobayashi; Frank R DeLeo
Journal:  J Innate Immun       Date:  2021-10-08       Impact factor: 7.111

4.  Treatment of Klebsiella pneumoniae septicemia in normal and leukopenic mice by liposome-encapsulated muramyl tripeptide phosphatidylethanolamide.

Authors:  P M Melissen; W van Vianen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.